Sandbox:farnaz: Difference between revisions
Jump to navigation
Jump to search
| Line 21: | Line 21: | ||
{{familytree | | | | | | | | | | | | | | | | E02 | | | | | | | | | | | |E03 | | | | | | | | | | | | E04 |E01=E01|E02=Direct injury to lung|E03=Hematogenous injury to lung|E04=Lung injury plus elevated hydrostatic pressure}} | {{familytree | | | | | | | | | | | | | | | | E02 | | | | | | | | | | | |E03 | | | | | | | | | | | | E04 |E01=E01|E02=Direct injury to lung|E03=Hematogenous injury to lung|E04=Lung injury plus elevated hydrostatic pressure}} | ||
{{familytree | | | | | |,|-|-|-|v|-|-|-|v|-|-|^|-|-|v|-|-|-|v|-|-|-|.| | |!| | | | | | | | | |,|-|-|-|+|-|-|-|.| }} | {{familytree | | | | | |,|-|-|-|v|-|-|-|v|-|-|^|-|-|v|-|-|-|v|-|-|-|.| | |!| | | | | | | | | |,|-|-|-|+|-|-|-|.| }} | ||
{{familytree | | | | | F01 | | F02 | | F03 | | | | F04 | | F05 | | F06 | |!| | | | | | | | | F07 | | F08 | | F09 | | | | | |F01=Chest trauma,pulmonary contusion|F02=Aspiration|F03=Smoke | {{familytree | | | | | F01 | | F02 | | F03 | | | | F04 | | F05 | | F06 | |!| | | | | | | | | F07 | | F08 | | F09 | | | | | |F01=Chest trauma,pulmonary contusion|F02=Aspiration|F03=Smoke inhalation|F04=Pneumonia|F05=Oxygen toxicity|F06=Pulmonary embolism,reperfusion|F07=High altitude pulmonary edema|F08=Neurogenic pulmonary edema|F09=Reexpansion pulmonary edema}} | ||
{{familytree | | | | | | | | | | | | | | | | | | | | | | |,|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|.| | | | | | | | | }} | {{familytree | | | | | | | | | | | | | | | | | | | | | | |,|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|.| | | | | | | | | }} | ||
{{familytree | | | | | | | | | | | | | | | | | | | | | | G01 | | G02 | | G03 | | G04 | | G05 | | | | | | | | | | | | | | |G01=Sepsis|G02=Pancreatitis|G03=Nonthoracic trauma|G04=Multiple transfusions|G05=Intravenous drug use. e.g. heroin|G06=Cardiopulmonary bypass}} | {{familytree | | | | | | | | | | | | | | | | | | | | | | G01 | | G02 | | G03 | | G04 | | G05 | | | | | | | | | | | | | | |G01=Sepsis|G02=Pancreatitis|G03=Nonthoracic trauma|G04=Multiple transfusions|G05=Intravenous drug use. e.g. heroin|G06=Cardiopulmonary bypass}} | ||
Revision as of 20:42, 12 February 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farnaz Khalighinejad, MD [2]
Overview
This is my sandbox.
Image reference
Source: Wikimedia commons
Type 1:
| Pulmonary edema | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cardiogenic | Non-cardiogenic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LV failure | Dysrthmia | LV hypertrophy and cardiomyopathy | Volume Overload | MI | LV outflow obstruction | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Direct injury to lung | Hematogenous injury to lung | Lung injury plus elevated hydrostatic pressure | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chest trauma,pulmonary contusion | Aspiration | Smoke inhalation | Pneumonia | Oxygen toxicity | Pulmonary embolism,reperfusion | High altitude pulmonary edema | Neurogenic pulmonary edema | Reexpansion pulmonary edema | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sepsis | Pancreatitis | Nonthoracic trauma | Multiple transfusions | Intravenous drug use. e.g. heroin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Type 2
The primary therapy for MS may include:[1][2]
- B-interferon
- Teleflunomide
96 patients (174 eyes, 70% females) were included with a mean age at presentation of 30 years
| Cause | Symptom | Diagnosis | Treatment |
|---|---|---|---|
| 1 | |||
| 2 | |||
| 3 |
References
- ↑ Kamm CP, Uitdehaag BM, Polman CH (2014). "Multiple sclerosis: current knowledge and future outlook". Eur Neurol. 72 (3–4): 132–41. doi:10.1159/000360528. PMID 25095894.
- ↑ Schwartz K, Wymbs NF, Huang H, Mealy MA, Pardo CA, Zackowski K; et al. (2017). "Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis". Mult Scler J Exp Transl Clin. 3 (4): 2055217317740145. doi:10.1177/2055217317740145. PMC 5731631. PMID 29270309.